Manage Tickers

Has my stock been accused of fraud?Join over 160k users who know.

Ticker Price Change($) Change(%) Shares Volume Prev Close Open Gain($) Gain(%)
Ticker Status Jurisdiction Filing Date CP Start CP End CP Loss Deadline
Ticker Case Name Status CP Start CP End Deadline Settlement Amt
Ticker Name Date Analyst Firm Up/Down Target ($) Rating Change Rating Current
Analyst Rating Guide

News

Back

Immix Biopharma Publishes And Presents Results For Cell Therapy NXC-201 Abstract #7508 At ASCO

Author: Benzinga Newsdesk | May 22, 2025 04:05pm

– NXC-201 demonstrated a complete response (CR) rate of 71% (5/7 patients) –

– No relapses recorded to-date; no safety signals identified –

– Updated results with a later data cutoff, including endpoint analysis, will be presented at ASCO by lead investigator Heather Landau, MD, of Memorial Sloan Kettering Cancer Center –

Posted In: IMMX


CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION

CORE Finalist